a b s t r a c t
We have discovered a fragment of the natural product roseophilin, a member of the prodiginine family, that antagonizes Mcl-1 functions in a liposome-based assay for mitochondrial membrane permeabilization. By tailoring this substance such that it can participate in salt bridging with the protein surface, we have prepared the first prodiginine inspired structure that shows direct, saturable binding to a recombinant Bcl-2 family member in vitro.
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Our laboratory is interested in small molecule mimics of regulatory proteins. Compounds that can restore apoptotic signaling in cancer cells are a particular focus. We described the first Smac mimetics in 2004. 1 Those molecules subsequently helped identify compounds that activate the TRAIL receptor. 2 The TRAIL/Smac mimetic combination selectively stimulates apoptosis by derepressing caspase activities. 3 Attention has recently shifted to a second mechanism that results in apoptosis being suppressed in cancer; namely, the failed release of pro-apoptotic factors (including Smac) from the outer membrane space of mitochondria as gated by Bcl-2 proteins. Pro-survival Bcl-2 proteins prevent pore formations in the mitochondrial membrane needed to propagate apoptosis. Bcl-2 activities are countered by interactions with 'BH3-only' regulatory proteins-which involve key a-helix/domain interactions. These contacts have been studied intensely for two decades. 4 Early screens by one of us (GCS) identified the bacterial pigment streptorubin B (1, Fig. 1 ) as an inhibitor of the Bcl-2/Bax interaction. 5 This discovery led to the development of obatoclax (2), a simplified indolic variant of 1 that entered human clinical trials as a pan Bcl-2 antagonist. 6 In functional settings, obatoclax promotes apoptosis by countering activities of anti-apoptotic Bcl-2 family members, including myeloid cell leukemia protein 1 (Mcl-1). Mcl-1 based resistance has limited other Bcl-2 inhibitor programs. 7 Obatoclax is a valuable structure, but it does have liabilities. Its pyrrolylpyrromethene core can generate reactive oxygen species when bound by copper 8 and, in protonated form, it can function as a chloride ion symporter. 9 In an attempt to identify variants of 2 lacking these activities, we looked to our recent synthesis of roseophilin (3) Fig. 1) .
The majority of compounds we screened in this assay behaved like roseophilin itself. Namely, they showed little activity. However, an N-tosylated derivative of the pyrrolylfuran segment of the natural product did function in this format. At 2 lM concentrations (vs 0.4 lM Mcl-1 in liposomes), compound 4 caused calcein release at a rate approaching that of obatoclax (data not shown). Additional experiments with 4 were complicated by its limited stability. However, acetylated variant 5 was a bench stable solid (mp = 162-165°C) that was near equipotent to 4 in the liposome assay ( Fig. 1) . 13 An intriguing characteristic of obatoclax was that it blocked functions of Mcl-1 and other anti-apoptotic Bcl-2 proteins in membrane environments, yet showed limited/variable affinity for those proteins in isolation. 14 We asked whether this was also true of 5. 3A) was identified using Fesik's seminal fragment-based discovery methods. 17 X-ray co-crystallography showed the compound inserted into a binding pocket beneath the groove used by BH3 helical peptides to bind at the Mcl-1 surface (Fig. 3C) . Its carboxylic acid lay at the mouth of this pocket and formed a salt-bridge with R263-an interaction normally made from the opposite direction by a conserved aspartic acid residue in BH3 peptides (see protein data bank entry 4HW4). While benzothiophene 7 and acetyl furan 5 were discovered independently using completely different lines of inquiry, the resemblance of key elements in the structures was uncanny. In the Mcl-1 bound conformation of 7, the distance between the carboxylate carbon and the center of the chlorodimethylphenoxy substituent was 8.4 Å. We could dock compound 5 into the same space occupied on Mcl-1 by 7 without unfavorable steric interactions (using AutoDock Vina). 18 In the docked conformation of 5, wherein the carbonyl oxygen was in closest proximity to R263, the distance between the carbonyl carbon and the center of the tolyl group was 8.3 Å. We also observed that primary alcohol 8, derived from reducing carboxylic acid 7 with LiAlH 4 , no longer had affinity for Mcl-1 measurable by ITC (Fig. 3B ). This suggested that salt bridging was a critical aspect of the 7/Mcl-1 interaction and that giving 5 the ability to interact with the protein similarly may be advantageous. Based on the docking experiments above, we chose to replace the methyl ketone in 5 with a carboxylic acid isostere-hoping to increase its affinity for Mcl-1 in the absence of membranes. We metalated pyrrolofuran 9 19 selectively at its 5 0 position with n-butyl lithium. Treatment of the lithiated species with ZnI 2 followed by tosylcyanide gave furanylnitrile 10 in 79% yield. 20 Desilylation of 10 and derivatization with p-TsCl afforded 11 in high yields. To complete the target isostere, azide was cycloadded to the nitrile in 11 using diethylaluminum azide. 21 This provided furanyl tetrazole 12 after careful workup with a Na 2 HPO 4 /H 3 PO 4 buffer solution (pH = 2.1). 22 The overall yield of 12 from 9 was 33% (Scheme 1). A mixture of regioisomeric N-methyl tetrazoles 16, which are unable to ionize via proton transfer, were prepared as controls. 23 Tetrazoles 12 and 16 were tested for specific binding to Mcl-1 using ITC. To our delight, compound 12 showed strong, saturable binding to the protein, whereas its N-methylated congeners 16 did not (Fig. 4A) . Compound 12 bound Mcl-1 in an apparent 1:1 stoichiometry with K D = 0.7 lM. There was no indication of solubility differences in ITC buffer that would account for its improved performance relative to 5 and 16.
Compound 12 also successfully drove pore formations in the artificial membranes of our liposomal assay (Fig. 4B) . Its activity exceeded that of 5 and obatoclax and was Mcl-1 dependent. Bak loaded proteoliposomes lacking Mcl-1 did not release calcein dye when treated with 12. Moreover, when Mcl-1 was replaced with Bcl-xL in the assay, 12 also had no effect (Fig. 5 ). This suggested a selectively for Mcl-1 over Bcl-xL which could be of value going forward. Toxic thrombocytopenia caused by ABT-737 in vivo has been correlated with Bcl-xL inhibition. 25 The discovery of Mcl-1 antagonist 5 and a rational means to convert that molecule into a prodginine-like structure (i.e., 12) having specific affinity for purified Mcl-1 holds considerable promise. Inhibition of anti-apoptotic Bcl-2 proteins by obatoclax is thought dependent on a supporting membrane environment. This could be true for 5 as well wherein its activity in liposomes (Fig. 1 ) may be driven by hydrophobic effects. In contrast, data for the 12/Mcl-1 interaction suggest a significant electrostatic component. Consistent with this idea, comparably performing Mcl-1 ligands could be generated using ionizable groups other than a tetrazole. We synthesized N-acyl sulfonamides 14 and 15 via primary carboxamide 13 as outlined in Scheme 1.
26,27 Both 14 and 15 functioned in the liposomal assay and bound to recombinant Mcl-1 in vitro (Fig. 4C) . While their affinity for the purified protein (K D = 3.4 and 2.3 lM, respectively) was less than that for 12, these derivatives are amenable to further medicinal chemistry. We are currently attempting to confirm hypothetical binding modes for 12 (Fig. 3D ), 14 and/or 15 using X-ray co-crystallography. We hope to understand performance of this compound series in detail and, ultimately, to identify refined structures that potently inhibit Mcl-1 dependent cancer cell growth in culture and block Mcl-1 dependent tumor progression in vivo.
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